Exceptional items comprised:
| XLS |
|
|
|
€ million |
2011 |
2010 |
Gain on the divestment of the Crop BioScience business/transaction costs |
157.1 |
–1.0 |
Gain on the divestment of the Théramex business |
18.6 |
68.6 |
Adjustment of previous exceptional items |
9.4 |
– |
Expenses for environmental protection measures |
–28.9 |
– |
Expenses for litigation Dey Inc., USA |
–4.4 |
–67.2 |
Selling price adjustments for the Electronic Chemicals business |
– |
–1.2 |
Exceptional items |
151.8 |
–0.8 |
In 2011, exceptional items included € 157.1 million from the divestment of the Crop BioScience business to Novozymes A/S as well as an additional gain of € 18.6 million from the sale of distribution rights in connection with the divestment of the Théramex business, which closed at the end of 2010. Furthermore, expenses of € 28.9 million were incurred for provisions set up for environmental protection measures. Additional expenses of € 4.4 million were recognized in connection with the Dey Inc., USA, litigation. Income from the adjustment of previous exceptional items resulted from the provisions set up in connection with the discontinuation of Raptiva®.